Floatz logo

Daunorubicin

Induction Therapy

Peking University People's HospitalN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the Induction Therapy cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Shanghai Chest Hospital
Phase 2CCC
Carboplatin
Shanghai Chest Hospital
Phase 2CCC
Iparomlimab
Shanghai Chest Hospital
Phase 2CCC
CIS-DIAMMINEDICHLOROPLATINUM II
Shanghai Chest Hospital
Phase 2CCC

Same molecule, other indications

Daunorubicin is also rated in:

acute myeloid leukemia by FAB classificationDormant
BBB
Indicative ·
78 / 100
View asset →
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
77 / 100
View asset →
acute monocytic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →